Article
ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.
The oncologist - 1 Dec 2017
Ross Jeffrey S, Ali Siraj M, Fasan Omotayo, Block Jared, Pal Sumanta, Elvin Julia A, Schrock Alexa B, Suh James, Nozad Sahar, Kim Sungeun, Jeong Lee Hwa, Sheehan Christine E, Jones David M, Vergilio Jo-Anne, Ramkissoon Shakti, Severson Eric, Daniel Sugganth, Fabrizio David, Frampton Garrett, Miller Vince A, Stephens Philip J, Gay Laurie M
Abstract excerpt
BACKGROUND: Genomic fusions of the anaplastic lymphoma kinase gene (ALK) are a well-established therapy target in non-small cell lung cancer (NSCLC). From a survey of 114,200 clinical cases, we determined the prevalence of ALK rearrangements (rALK) in non-NSCLC tumors and report their responsiveness to therapies targeting ALK. MATERIALS AND METHODS: Comprehensive genomic profiling of 114,200 relapsed and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.